Pivotal readout

Orelabrutinib hits primary goal in Chinese phase 3 study in chronic ITP

InnoCare Pharma said its BTK inhibitor orelabrutinib beat placebo in a 196-patient phase 3 trial in adults with previously treated chronic immune thrombocytopenia. Durable platelet response reached 32.8%, a 25.5-point gain over placebo (P=0.0001), and safety resembled placebo. The data will be an oral talk at ASH; a Chinese filing for this use was accepted in May.

Written by Gosset from public sources. Source types: News article. Sources are available to Gosset users. Log in to see them.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call